Introduction {#Sec1}
============

Circulating cell-free (cf) DNA is thought to be secreted in the blood circulation through necrosis, apoptosis or active release from nucleated cells. Inflammation, trauma and malignancy have been linked with elevated concentrations of cfDNA \[[@CR1]\]. Based on the observed release of DNA from tumoral cells during processes such as necrosis and apoptosis, plasma cfDNA is regarded as a source of tumor DNA for the purposes of early detection of cancer and patients' follow-up \[[@CR2]\]. High mortality rate of lung cancer and poor patients' outcome have prompted researchers to find suitable biomarkers for this kind of cancer. High cf DNA concentrations at baseline have been associated with worse patients' outcome of cancer patients in some studies \[[@CR2]\]. Moreover, the clinical validity of measurement of cfDNA for the estimation of lung cancer survival has been confirmed through meta-analysis of available literature \[[@CR3]\]. Besides, quantification of cfDNA has a diagnostic accuracy comparable with conventional blood-based biomarkers for lung cancer screening \[[@CR4]\]. Moreover, specific mutations found in cfDNA could act as prognostic and predictive biomarkers for patients with non-small cell lung cancer (NSCLC). For instance, the presence of EGFR activating mutations in cfDNA of these patients has been regarded as a predictive marker for response to EGFR-tyrosine kinase inhibitors \[[@CR5]\]. Specifically, the L858R EGFR mutation in cfDNA could predict the overall survival of NSCLC patients \[[@CR6]\].

Although several studies have quantified circulating cfDNA in lung cancer patients, no definite evidence indicates the associations between its concentrations and tumor features. The inconsistencies between the results of former studies might be originated from the method of cfDNA quantification. Consequently, in the present study we aimed at quantification of cfDNA in Iranian lung cancer patients with two commercially available kits to find the associations between its concentration and patients' clinical data in a comparative manner.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

A total of 44 patients with NSCLC participated in the current study. Patients were hospitalized in Masih Daneshvari Hospital, Tehran during April 2017 to May 2018. The recurrence after initial treatment and patients' outcome were recorded. All patients had performance status of 1--2 based on the Eastern Cooperative Oncology Group (ECOG) criteria \[[@CR7]\]. The study protocol was approved by ethical committee of Tehran University of Medical Sciences. Written informed consent forms were signed by all study participants.

Assessment of free DNA concentrations {#Sec4}
-------------------------------------

Venous blood was gathered in sterile EDTA-coated tubes. Samples were centrifuged at 590×*g* for 15 min in room temperature. Isolated plasma samples were kept at − 80 °C. cfDNA was extracted from plasma samples using the QIAamp Circulating Nucleic Acid Kit (QIAGEN, Valencia, CA, USA) and NucleoSpin Plasma XS (MN, Germany). cfDNA concentrations were quantified using NanoDrop 2000 (Thermo Scientific). Total concentrations of cf DNA in the plasma were reported. The same volume of plasma was used for cf DNA extraction from all samples (2 ml for extraction with QIAGEN kit and 260 µl for extraction with MN kit based on the guidelines provided by the companies).

Statistical analyses {#Sec5}
--------------------

Statistical analyses were performed in SPSS v.18.0 (IBM Corp., Armonk, NY, USA). Data were reported as mean ± standard deviation (SD). Paired-samples t test was used for comparison of concentrations of cfDNA in each sample as measured by each kit. The significance of association between cfDNA concentrations and tumor features was assessed using independent-samples t test. For all statistical analyses, P \< 0.05 was considered as significant. The receiver operating characteristic (ROC) curve was designed to evaluate the suitability of cfDNA concentrations for prediction of recurrence probability and metastatic potential. The Youden index (j) was used to maximize the difference between sensitivity (true-positive rate) and 1---specificity (false-positive rate).

Results {#Sec6}
=======

General clinical information of patients {#Sec7}
----------------------------------------

The current study included 44 patients with NSCLC. Patients were followed up until October 2018. During follow-up period 12 of them died. Blood samples were taken from patients before any cancer treatment at initial visit. Table [1](#Tab1){ref-type="table"} shows General demographic and clinical data of patients.Table 1General demographic and clinical data of patientsVariablesValuesAge (mean ± SD (range))59.79 ± 11.65 (34--84)Cell free DNA concentration---MN Kit (mean ± SD (range)) (ng/ml)13.92 ± 4.11 (3.6--22.3)Cell free tumor DNA---QIAGEN Kit (mean ± SD (range)) (ng/ml)19.1 ± 6.03 (6.1--32.6)Recurrence after (month) (mean ± SD (range))7.76 ± 5.4 (1--19)Gender Male45.5% Female54.5%Smoking Yes22.7% No77.3%Stage II2.3% III4.5% IV93.2%Recurrence Yes56.8% No43.2%Current status Alive67.6% Dead32.4%Metastasis Non metastatic11.4% Metastasis to one organ68.1% Metastasis to two organ9.1% Metastasis to three organ11.4%

Comparison of circulating free DNA concentrations as detected by two methods {#Sec8}
----------------------------------------------------------------------------

The mean values (± standard deviation) of circulating DNA concentrations as measured simultaneously by two methods were 13.72 (3.95) (ng/ml) and 19.1 (6.03) (ng/ml) for MN and QIAGEN kits respectively (P \< 0.001).

Association between circulating free DNA concentration and patients' characteristics {#Sec9}
------------------------------------------------------------------------------------

Primary cfDNA concentrations (ng/ml) as measured by QIAGEN kit was significantly higher in patients who died in the follow-up period compared with alive patients (P = 0.007). Moreover, the concentrations as measured by both methods were higher in patients who experienced recurrence in the follow-up period compared with patients without recurrence (P = 0.008 and 0.007 for MN and QIAGEN kits respectively). Significant associations were also found between cfDNA concentrations and tumor stage (P = 0.005 and 0.02 for MN and QIAGEN kits respectively). Notably, cfDNA concentration was higher in metastatic tumors compared with non-metastatic tumors in association with number of involved organs (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). Table [2](#Tab2){ref-type="table"} shows associations between cfDNA concentration and patients' characteristics.Fig. 1Circulating free DNA concentrations (ng/ml) in association with metastasis potential Table 2Association between cf DNA concentration (ng/mL) and patients' characteristicscfDNA concentration (MN kit) (ng/ml)P valuecfDNA concentration (QIAGEN kit) (ng/ml)P valueGenderMale vs. female13.96 (4.67) vs. 13.88 (3.69)0.9419.21 (6.59) vs. 19.01 (5.67)0.91SmokingYes vs. no13.96 (4.55) vs. 13.9 (4.05)0.9719.17 (6.1) vs. 19.08 (6.1)0.96Current statusAlive vs. dead13.22 (4.56) vs. 16.21 (3.4)0.0517.56 (5.78) vs. 23.49 (6.28)0.007RecurrenceYes vs. no15.81 (3.45) vs. 12.06 (4.7)0.00821.93 (6.09) vs. 16.27 (5.7)0.007StageII and III vs. IV7.66 (2.5) vs. 14.37 (3.84)0.00511.43 (2.05) vs. 19.66 (5.84)0.02MetastasisNon metastatic vs. Metastasis to one organ7.94 (3.81) vs. 13.69 \[[@CR3]\]0.0211.1 (3.52) vs. 18.71 (4.73)0.01Non metastatic vs. Metastasis to two organs7.94 (3.81) vs. 16.5 (2.29)0.00111.1 (3.52) vs. 23.5 (4.98)0.002Non metastatic vs. Metastasis to three organ7.94 (3.81) vs. 19.18 (3.45)\< 0.00111.1 (3.52) vs. 25.92 (6.24)\< 0.001Metastasis to one organ vs. Metastasis to two organs13.69 \[[@CR3]\] vs. 16.5 (2.29)0.3318.71 (4.73) vs. 23.5 (4.98)0.26Metastasis to one organ vs. Metastasis to three organs13.69 \[[@CR3]\] vs. 19.18 (3.45)0.00418.71 (4.73) vs. 25.92 (6.24)0.01Metastasis to two organs vs. Metastasis to three organs16.5 (2.29) vs. 19.18 (3.45)0.5723.5 (4.98) vs. 25.92 (6.24)0.87

After partial correction for patients' gender, circulating DNA concentrations (ng/ml) were not correlated with either age of patients or recurrence time after initial diagnosis (Table [3](#Tab3){ref-type="table"}).Table 3Partial correlation between free DNA concentrations (ng/ml) and age/recurrence time (controlled for gender)cfDNA concentration (MN kit) (ng/ml)cfDNA concentration (QIAGEN kit) (ng/ml)RP valueRP valueAge− 0.230.06− 0.180.12Recurrence time− 0.050.4− 0.190.2

ROC curve analysis {#Sec10}
------------------

We evaluated diagnostic power of cfDNA concentration for prediction of recurrence probability and metastatic potential (Table [4](#Tab4){ref-type="table"}). Both kits had 100% sensitivity for differentiation of recurrence probability (Fig. [2](#Fig2){ref-type="fig"}). Based on the AUC values, both kits could differentiate metastatic cancers from non-metastatic ones with accuracy of 98% (Fig. [3](#Fig3){ref-type="fig"}).Table 4The results of ROC curve analysisDifferentiation of recurrence probabilityDifferentiation of metastatic potentialEstimate criterionAUCJ^a^SensitivitySpecificityP-value^b^ Estimate criterionAUCJ^a^SensitivitySpecificityP-value^b^ MN\> 11.30.710.4310043.70.01\> 10.10.980.9595100\< 0.001QIAGEN\> 15.10.740.5100500.004\> 130.980.9797.5100\< 0.001^a^Youden index, ^b^Significance level P (Area = 0.5), Estimate criterion: optimal cut-off point for cf DNA concentration Fig. 2ROC curve analysis for assessment of diagnostic power of cf DNA concentrations for differentiation of recurrence probability Fig. 3ROC curve analysis for assessment of diagnostic power of cf DNA concentrations (ng/ml) for differentiation of metastatic potential

Discussion {#Sec11}
==========

Lung cancer is a human malignancy associated with high mortality rate. Several prognostic factors including tumor stage, performance status, age at diagnosis and response to first-line chemotherapy have been recognized for this kind of cancer \[[@CR8]\]. In the present study, we first quantified cfDNA levels in lung cancer patients and then assessed associations between cfDNA concentrations and some of known prognostic factors for lung cancer. Previous studies have measured cfDNA levels using different methods such as spectrophotometry \[[@CR9]\], digital polymerase chain reaction (PCR)-based technologies \[[@CR10]\] or Alu81-quantitative PCR \[[@CR11]\]. We used two commercially available kits for isolation of cfDNA and subsequently quantified cfDNA using NonoDrop equipment. Notably, we found significant associations between cfDNA concentration and some clinical features such as stage, recurrence and metastatic potential. Although we found significant difference in the cfDNA concentration as measured by the mentioned commercially available kits, associations remained significant even when the reported concentrations were low (with MN method). This finding shows the validity of our obtained results. Moreover, cfDNA concentrations were not associated with patients' age, sex or smoking history which shows the suitability of this source of biomarker for identification of disease status independent of these features. Although the cfDNA levels were associated with recurrence potential, after partial correction for patients' gender, cfDNA concentrations were not correlated with recurrence time after initial diagnosis which might be explained by the relative low number of samples. Notably, cfDNA concentrations were not only predictive of metastatic potential, but also they could predict the number of involved organs which is potentially indicative of poor outcome. Based on the AUC values, diagnostic power of cfDNA concentration for prediction metastatic potential was higher than its ability to predict recurrence. Such diagnostic power was also independent of isolation method.

In brief, our study highlights the suitability of liquid biopsy as a non-invasive method for prediction of lung cancer prognosis in Iranian patients. As in the present study, we only assessed baseline cfDNA concentrations, future studies are needed to assess cfDNA levels in certain intervals after administration of drugs to explore their relevance with response of patients to each therapeutic regimens. We also showed availability of these methods for clinical practice and could solve the technical problems that were related to the evaluation of the cfDNA concentrations in the blood circulation. The similar results obtained from two mentioned kits indicate the reproducibility of the data.

Conclusion {#Sec12}
==========

Based on the results of previous studies indicating that the diagnostic accuracy of quantitative investigation of cfDNA is not inferior to conventional peripheral biomarkers for lung cancer screening \[[@CR12]\], such approaches can be used for initial screening of cancer patients as well. However, studies in large sample sizes are needed to explore the differences in cfDNA concentrations between normal individuals, precancerous conditions and cancer patients.
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